Theriva Biologics Inc TOVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.23
- Day Range
- $0.23–0.23
- 52-Week Range
- $0.16–0.86
- Bid/Ask
- $0.23 / $0.23
- Shares Outstanding
- 45.89M
- Market Cap
- $10.62M
- Volume/Avg
- 229,375 / 21M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.24
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
- Website
- https://www.therivabio.com
Valuation
|
Metric
|
TOVX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.68 |
Price/Sales | 9.24 |
Price/Cash Flow | — |
Price/Earnings
TOVX
Financial Strength
|
Metric
|
TOVX
|
|---|---|
Quick Ratio | 1.58 |
Current Ratio | 1.63 |
Interest Coverage | — |
Quick Ratio
TOVX
Profitability
|
Metric
|
TOVX
|
|---|---|
Return on Assets (Normalized) | −59.24% |
Return on Equity (Normalized) | −163.18% |
Return on Invested Capital (Normalized) | −134.08% |
Return on Assets
TOVX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$ckR@s | LOCK|y<CHj | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|K$t#X% | LOCK|lpS<# | $70B | |||
| argenx SE ADR
ARGX
| LOCK|#SY!&F< | LOCK|t$ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!&W@T$X | LOCK|Q?<w& | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|kvnfhp | LOCK|!<@ | $37B | |||
| Moderna Inc
MRNA
| LOCK|?@W@X# | LOCK|p>Y | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|dtVjmq? | LOCK|FS!% | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|>NN^sH | LOCK|$@x | $23B | |||
| Incyte Corp
INCY
| LOCK|@JDYgY& | LOCK|NC | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|b@Jvsk> | LOCK|rW$ | $16B |
United States